Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,680 annual reports · 4,010 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 594 of 640 · 7,680 filings

  • Vertex Pharmaceuticals (VRTX) FY2024 10-K risk factors
    50 risks

    CF medicines generate substantially all recent net product revenue, making continued CF sales the company’s dominant financial dependency.

    Filed Feb 13, 2025
  • Hyatt Hotels (H) FY2024 10-K risk factors
    60 risks

    Hyatt’s risk section is dominated by dependence on third-party owners, franchisees, venture partners, and development pipelines.

    Filed Feb 13, 2025
  • Church & Dwight (CHD) FY2024 10-K risk factors
    35 risks

    Retail concentration and competition dominate, with Walmart representing 23% of 2024 net sales and the top four customers 43%.

    Filed Feb 13, 2025
  • Corning (GLW) FY2024 10-K risk factors
    10 risks

    Corning emphasizes risks to its innovation model, including uncertain returns on R&D and dependence on specialized glass, ceramic, and optical expertise.

    Filed Feb 13, 2025
  • Phinia (PHIN) FY2024 10-K risk factors
    30 risks

    PHINIA’s biggest strategic risk is adapting fuel-system and electrical products to tighter emissions rules and faster electric-vehicle adoption.

    Filed Feb 13, 2025
  • State Street (STT) FY2024 10-K risk factors
    67 risks

    Fee revenue is approximately 78% of total revenue, making client investment activity and asset mix central to performance.

    Filed Feb 13, 2025
  • Travelers Companies (TRV) FY2024 10-K risk factors
    23 risks

    Catastrophes, climate conditions, asbestos, environmental and mass-tort claims dominate Travelers’ underwriting exposure.

    Filed Feb 13, 2025
  • American Electric Power (AEP) FY2024 10-K risk factors
    17 risks

    Transmission investment earnings depend heavily on FERC and state policy, while regulation can delay projects or limit cost recovery.

    Filed Feb 13, 2025
  • Agios Pharmaceuticals (AGIO) FY2024 10-K risk factors
    54 risks

    Commercializing PYRUKYND and advancing clinical candidates dominate this risk profile. Dependence on third-party manufacturers, clinical sites, and collaborative partners is critical. Intellectual property protection and regulatory pricing pressures heavily influence future viability.

    Filed Feb 13, 2025
  • Alnylam Pharmaceuticals (ALNY) FY2024 10-K risk factors
    56 risks

    Alnylam faces substantial financial risks with an accumulated deficit of $7.29 billion as of December 31, 2024. The company relies heavily on commercial success for AMVUTTRA and royalties from Leqvio. Operations depend on third-party manufacturing, clinical trial execution, and complex global intellectual property licensing. Regulatory pricing pressures and compliance across international jurisdictions present ongoing challenges.

    Filed Feb 13, 2025
  • Allison Transmission Holdings (ALSN) FY2024 10-K risk factors
    32 risks

    Allison faces high cyclicality in markets like energy and construction, heavy reliance on single-source suppliers and UAW labor, and significant debt of $2,414 million.

    Filed Feb 13, 2025
  • Axalta Coating Systems (AXTA) FY2024 10-K risk factors
    42 risks

    Axalta faces significant customer concentration, with its largest customer and distributor accounting for 5% and 3% of 2024 net sales respectively. Manufacturing relies heavily on a small number of facilities vulnerable to disruption. Operations involve hazardous materials, strict global environmental regulations, and variable rate debt tied to SOFR.

    Filed Feb 13, 2025

Companies covered

4,010 companies

371 more under A